J & J receives FTC clearance of the proposed acquisition of Guidant, informed of Transaction in Light of Guidant Recall EventsJohnson & Johnson was informed that the Federal Trade Commission has caused the proposed acquisition of Guidant approved Corporation . The FTC clearance to Johnson & Johnson conditioned sale of certain rights and assets of the companies in drug – eluting stents, endoscopic vessel harvesting products and anastomotic assist devices.
Johnson & Johnson continues to see the announced recalls of Guidant and the related regulatory investigations, claims and other developments as serious matters, both Guidant short-term results and long-term prospects. Johnson & Johnson believes that these events have a material adverse effect on Guidant, and as a result, that it is not required under the terms of of the merger agreement to close the Guidant acquisition. Johnson & Johnson has had discussions with Guidant to restructure the terms of the transaction, no agreement between the company.Overall, Danish doctors to use technology as part of their periodically fulfills practical they report increased efficiency, fast access to patient records, better coordination with hospitals and emergency rooms and storage about one hour out of personnel time each day to for the for the investment in the technique. 46,300,000 uninsured or where they live? Related KHN Content: As health overhaul would be affecting which assured.